Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 22, 2011 Dan Radovsky	Should Icahn's Interest in Clorox Perk Yours? Does corporate raider Carl Icahn want to clean Clorox's house for himself, or does he just want to flip it for a quick profit?
The Motley Fool July 18, 2011 Rich Smith	Carl Icahn's Clorox Pipedream Icahn announced that he wants to up his 9.4% stake in Clorox, bidding to buy the whole company for $76.50 per share.
The Motley Fool March 30, 2011 Anders Bylund	Mentor Could Use Some Guidance Is the company looking to preserve shareholder interest or management paychecks?
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool August 22, 2011 Jeff Bailey	Fending Off Icahn, Clorox Takes It Out on Consumers With Big Price Hikes Does Clorox still look like a bargain?
The Motley Fool September 29, 2011 Evan Niu	Does HP Need a Poison Pill? HP may have tapped Goldman Sachs to defend itself against activist investors.
The Motley Fool December 15, 2010 Toby Shute	This Corporate Raider Hasn't Lost His Touch Has Carl Icahn outsmarted Blackstone with his bid for utility company Dynegy? The tentative answer today appears to be yes.
InternetNews November 14, 2007 Larry Barrett	BEA to File Past-Due Financial Reports BEA Systems will try to save its Nasdaq listing and protect itself from future proxy fights with shareholders.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool December 7, 2006 Dan Caplinger	Don't Swallow the Poison Pill Corporate takeovers are often profitable for investors, so why stop them?
The Motley Fool November 7, 2005 Jeremy MacNealy	Can Clorox Remove This Stain? Clorox is a solid company in many ways, but it competes with consumer goods rivals and struggles with increased energy-related costs. Investors, take note.
InternetNews November 16, 2007 Larry Barrett	Oracle Content Without BEA Oracle's CEO Larry Ellison made it clear the company has no intention to sweeten its original offer for BEA Systems.
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool December 19, 2005 Seth Jayson	Clorox Brightens Forecast Clorox's guidance is a bit better. That may be enough to make the shares cheap. Investors on the lookout for a premium company at a bargain price may not have to wait much longer.
The Motley Fool January 11, 2012	What Clorox Does With Its Cash Over the last five years, Clorox shares have returned 24%, which drops to 7% without dividends -- not a bad boost to top off otherwise low share performance.
The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
The Motley Fool October 24, 2011	A Brief History of Clorox's Returns Clorox shares returned 145% over the past decade. How'd they get there?
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool February 1, 2006 Rich Smith	Foolish Forecast: Clorox Comes Clean Over the past four quarters, Clorox's rolling margin results have fallen consecutively in the gross, operating, and net categories. Investors, take note.
The Motley Fool September 3, 2010 Matt Koppenheffer	How Much Is Clorox Worth? Clorox is a stable company with a portfolio of strong brands, opportunity to grow both domestically and internationally, and its stock may be on sale right now.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool June 22, 2011	Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool October 22, 2010 Anand Chokkavelu	3 Brand-Name Stocks Near 52-Week Lows Here are the top three companies in the brand name space (by market cap) that are hugging 52-week lows: Colgate-Palmolive... Kimberly-Clark... Clorox...
The Motley Fool August 4, 2010 Matt Koppenheffer	Clorox? More Like Snore-ox! Clorox announces its fiscal fourth-quarter and full-year earnings.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool February 7, 2005 Stephen D. Simpson	Bright, But Not Bold, Clorox Steady but unspectacular growth might leave investors wanting a bit more kick.
The Motley Fool October 15, 2007 Anders Bylund	BEA Plays a Fool's Game A multi-billion-dollar bidding war is about to start. Or is it? Buying BEA stock today is a gamble that the company's price tag will grow before an eventual sale. A sensible investor might take the gains here and go look for a safer bet.
The Motley Fool January 12, 2011 Andrew Bond	This Stock Is a Lot Sexier Than You Think While Clorox's products bore many, its returns are more exciting.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool January 18, 2011 Matt Koppenheffer	Why Do Investors Hate This Stock? Investors seem to hate Clorox but there's no good reason why.
The Motley Fool February 17, 2010 Anders Bylund	Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney?
The Motley Fool July 8, 2008 Rick Aristotle Munarriz	Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!.
The Motley Fool May 4, 2011 Matt Koppenheffer	Clorox Is Yet Another Victim Higher commodity costs are chipping away at margins.
InternetNews March 24, 2008	Icahn Sues Motorola to Get Access to Documents Investor Carl Icahn said on Monday he is suing Motorola to force it to hand over documents related to its mobile devices business, and he urged investors to elect his slate of candidates to the Motorola board.
National Real Estate Investor December 4, 2002 Parke Chapman	Investor now holds 6.9% stake in Insignia Carl Icahn now holds a 6.9% stake in real estate operator Insignia Financial Group Inc.
The Motley Fool April 12, 2010 Rick Steier	Clorox: When a Stalwart Lets You Down Clorox is a waste of an investment.
The Motley Fool March 23, 2005 Stephen D. Simpson	Kerr-McGee Gets the Message Will this deepwater driller, a historical underachiever, succeed in acting in shareholders' best interests?
The Motley Fool September 1, 2005 Steven Mallas	Time for Time Warner? Time Warner has seen some interesting times lately. Should you buy the stock?
The Motley Fool May 20, 2005 Steven Mallas	Clorox: A Fresh Idea? Clorox has a nice history of long-term performance -- but should you buy it now?
InternetNews January 30, 2007 Ed Sutherland	Icahn Has Motorola in His Sites News Wall Street trader Carl Icahn wants a spot on Motorola's board sent tongues wagging and stock prices up.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool July 23, 2008 Rick Aristotle Munarriz	Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane?
The Motley Fool September 1, 2009 Rick Aristotle Munarriz	Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%.
The Motley Fool May 5, 2005 Rick Aristotle Munarriz	Make It a Blockbuster Fight Blockbuster and Carl Icahn are just days away from a battle at the company's shareholder meeting. Given Blockbuster's deteriorating financials and the sector's quickly changing landscape, it's hard to value the company based on its future prospects.